At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 72 enrolled
Drug / intervention
Empagliflozin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
EMPA-VISION: A Randomised, Double-blind, Placebo-controlled, Mechanistic Cardiac Magnetic Resonance Study to Investigate the Effects of Empagliflozin Treatment on Cardiac Physiology and Metabolism in Patients With Heart Failure
In Brief
A Phase 3 clinical trial evaluating Empagliflozin and Placebo for Heart Failure. Completed, enrolled 72 participants across 1 site.
Detailed Summary
The objective of this trial is to assess the effect of empagliflozin on cardiac physiology and metabolism aiming to provide a scientific explanation of the underlying mechanism by which empagliflozin improves HF related outcomes in patients with chronic heart failure
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure
CountriesUnited Kingdom
CollaboratorsEli Lilly and Company
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedNov 2017
Enrollment StartMar 2018
Primary CompletionMay 2020
Study CompletionMay 2020
TodayJul 2026
First PostedNov 6, 2017
Enrollment StartMar 1, 2018
Primary CompletionMay 21, 2020
Study CompletionMay 28, 2020
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 8.7 years ago
Interventions
Empagliflozindrug
12 weeks
Placebodrug
12 Weeks